Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.
Volatility and Risk
Finch Therapeutics Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.
Valuation and Earnings
This table compares Finch Therapeutics Group and Poseida Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Finch Therapeutics Group | $110,000.00 | 161.91 | -$74.75 million | ($10.14) | -1.09 |
| Poseida Therapeutics | $88.46 million | 3.39 | -$123.43 million | ($1.19) | -2.60 |
Analyst Ratings
This is a summary of recent recommendations and price targets for Finch Therapeutics Group and Poseida Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Finch Therapeutics Group | 0 | 0 | 0 | 0 | N/A |
| Poseida Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Poseida Therapeutics has a consensus price target of $14.67, suggesting a potential upside of 358.33%. Given Poseida Therapeutics’ higher possible upside, analysts clearly believe Poseida Therapeutics is more favorable than Finch Therapeutics Group.
Profitability
This table compares Finch Therapeutics Group and Poseida Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Finch Therapeutics Group | N/A | -69.14% | -26.92% |
| Poseida Therapeutics | -127.48% | -121.01% | -39.66% |
Insider & Institutional Ownership
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 2.9% of Poseida Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Finch Therapeutics Group beats Poseida Therapeutics on 8 of the 13 factors compared between the two stocks.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
About Poseida Therapeutics
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.
